Holen Sie sich die Stockscreener-App
33.43
2.92%
0.95
Handel nachbörslich:
33.43
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality - simplywall.st
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Announces First Quarter 2025 Financial Results | SUPN S - GuruFocus
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
SUPERNUS PHARMACEUTICALS Earnings Results: $SUPN Reports Quarterly Earnings - Nasdaq
Earnings Flash (SUPN) Supernus Pharmaceuticals Q1 Loss Per Share $0.21 Vs. FactSet Est. Loss $0.01 - marketscreener.com
Supernus Announces First Quarter 2025 Financial Results | SUPN Stock News - GuruFocus
Supernus Announces First Quarter 2025 Financial Results - GlobeNewswire
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationSUPN - ACCESS Newswire
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview - Nasdaq
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - Louisiana First News
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
How To Trade (SUPN) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Supernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade) (NASDAQ:SUPN) - Seeking Alpha
BlackRock, Inc. Reduces Stake in Supernus Pharmaceuticals Inc - GuruFocus
Supernus Pharmaceuticals (NASDAQ:SUPN) investors are up 6.5% in the past week, but earnings have declined over the last five years - simplywall.st
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals - The Globe and Mail
What Makes Supernus (SUPN) a New Buy Stock - Yahoo Finance
Investor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Envestnet Asset Management Inc. Has $2.17 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
LPL Financial LLC Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):